ZEPOSIA

This brand name is authorized in Austria, Australia, Canada, Estonia, France, Hong Kong, Croatia, Ireland, Israel, Italy, Lithuania, Netherlands, New Zealand, Poland, Romania, United Kingdom, United States

Active ingredients

The drug ZEPOSIA contains one active pharmaceutical ingredient (API):

1 Ozanimod UNII 3UPR33JAAM - OZANIMOD HYDROCHLORIDE

Ozanimod is a potent sphingosine 1-phosphate (S1P) receptor modulator, which binds with high affinity to sphingosine 1-phosphate receptors 1 and 5. Ozanimod has minimal or no activity on S1P~2, S1P3, and S1P4. In vitro, ozanimod and its major active metabolites demonstrated similar activity and selectivity for S1P1 and S1P5. The mechanism by which ozanimod exerts therapeutic effects in MS and UC is unknown, but may involve the reduction of lymphocyte migration into the central nervous system (CNS) and intestine. Read about Ozanimod

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
ZEPOSIA Hard capsule	European Medicines Agency (EU)	MPI, EU: SmPC
ZEPOSIA Capsule	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L04AE02		L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AE Sphingosine-1-phosphate (S1P) receptor modulators
Discover more medicines within L04AE02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 12271W, 12278F
Country: CA	Health Products and Food Branch	Identifier(s): 02505991, 02506009
Country: EE	Ravimiamet	Identifier(s): 1820854, 1820876, 1820966
Country: FR	Base de données publique des médicaments	Identifier(s): 62377435, 69203387
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 391303, 391306, 391309, 391312
Country: HK	Department of Health Drug Office	Identifier(s): 67126, 67127
Country: IE	Health Products Regulatory Authority	Identifier(s): 89088, 89089
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 8798, 8799, 8800
Country: IT	Agenzia del Farmaco	Identifier(s): 048818013, 048818025, 048818037
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1090323, 1090324, 1090325
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 203939, 203947
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 22323, 22324
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100438934, 100438940
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W67064001, W67065001, W67065002
Country: US	FDA, National Drug Code	Identifier(s): 59572-820